37 results about "Urination disorder" patented technology

The invention discloses a new Chinese medicinal composition for treating medial headache and migraine and a preparation method thereof. The Chinese medicinal composition comprises the following raw material medicaments: szechuan lovage rhizome, root of red-rooted salvia, costustoot, fenugreek lysimachia, benzoin, tangerine peel, radix curcumae, cyperus rotunus, golden thread, baical skullcap root, cassia twig, incised notopterygium rhizome, angelica dahurlica, kudzuvine root, peach seed, safflower, common burreed rhizome, zedoary, pangolin scales, raw astragalus, radix paeoniae alba, red paeony root, tall gastrodia tuber, gambir plant, storax, grassleaf sweelflag rhizome, fineleaf schizonepeta herb, divaricate saposhnikovia root, radix ephedrae, weeping forsythia, manchurian wildginger, biond magnolia flower, mentha haplocalyx, raw rehmannia root, szechwan chinaberry fruit, rose, radix pseudo-ginseng, rosewood heart wood, garden burnet root, leonurus heterophyllus, cowherb seed, ground beeltle, sappan wood, dragon's blood, pinellia tuber and the like. The Chinese medicinal composition can be prepared into any oral administration preparation used commonly according to the conventional method of Chinese medicinal preparations. The Chinese medicinal composition can improve headaches of bitamporal, foreheads and orbital parts, pulsatile headache or boring pain and the like, and associated symptoms of nausea, vomiting, blurred vision, frequent micturition, urination disorder, stuffy nose, palpitation, hypertension, hypotension, arrhythmia, megrim, ataxia, diplopia, hearing loss, tinnitus, disturbance of consciousness and the like obviously, and has definite clinical effects, obvious curative effect and quick response. The Chinese medicinal composition of the invention is combined by adopting medicinal and edible medicaments formulated by National Formulary basically, and thus, the Chinese medicinal composition has the advantages of low cost and no toxic or side effect.

The invention discloses a novel traditional Chinese medicinal composition for treating ovarian cyst and a preparation method thereof. The traditional Chinese medicinal composition mainly comprises the following raw material medicines: pangolin scales, tribulus terrestris, spina gleditsiae, rhizoma sparganii, zedoary, leech, ground beeltle, aspongopus, dragon's blood, Chinese trumpet creeper, cowherb seed, suberect spatholobus stem, twotooth achyranthes root, motherwort herb, peach kernel, red flower, szechuan lovage rhizome, immature bitter orange, szechwan chinaberry fruit, pseudoginseng root, cyperus rotundus, Chinese eaglewood and the like. The traditional Chinese medicinal composition can be prepared into any common oral preparation according to the conventional traditional Chinese medicinal preparation method, can obviously improve abnormal menstruation caused by myoma of uterus, colporrhagia, increased leucorrhea, abdomen bilge pendant, abdominal pain, frequent micturition and urination disorder due to myoma pressure on the bladder, constipation and impeded defecating due to myoma pressure on the rectum and other symptoms, and has the advantages of obvious inhibition of cyst hyperplasia, prevention of cancerization, exact clinical curative effect, obvious curative effect, quick response, low cost, fundamentally no toxic or side effect, and the like.

The invention provides a bladder function recovery apparatus. The bladder function recovery apparatus comprises an irrigation device, a urine drainage device, a bladder pressure acquisition unit and a central processing unit. The irrigation device comprises an irrigation bag, an irrigation tube and a first control component and is used for charging liquid medium in the irrigation bag to a bladder. The urine drainage device comprises a drainage bag, a urine drainage tube and a second control component and is used for draining the liquid medium in the bladder into the drainage bag. The bladder pressure acquisition unit is communicated with the urine drainage device. The central processing unit is connected with the first control component, the second control component and the bladder pressure acquisition unit and compares bladder pressure with maximal preset pressure and minimal preset pressure. When the bladder pressure is equal to or larger than the preset pressure, the first control component is closed, and the second control component is opened. When the bladder pressure is smaller than or equal to the minimal preset pressure, the second control component is closed, and the first control component is opened. The bladder function recovery apparatus can be used for bladder function recovery training for a patient with an indwelling catheter, and cystatrophy caused by long-term urination disorder is prevented.

The invention discloses a kidney essence pill formula for treating chronic pyelonephritis and a preparation method of the kidney essence pill, belonging to the technical field of traditional Chinese medicine formula. The kidney essence pill comprises the following raw materials of effective ingredients in parts by weight: 20-38g of rhizoma smilacis glabrae, 15-30g of Chinese yam, 15-30g of phymatopsis hastata, 10-30g of red bean, 10-30g of semen coicis, 12-28g of oyster, 9-24g of tortoise shell, 6-15g of morinda officinalis, 9-15g of lophatherum gracile, 7-15g of cortex lycii radicis, 5-12g of rhizoma alismatis, 4-12g of sparganii rhizoma, 4-10g of earthworm, 3-11g of myrrh, 3-9g of salvia miltiorrhiza, 3-9g of golden cypress, 3-8g of tangerine seed, and 1-3g of endothelium corneum gigeriae galli. The kidney essence pill formula is perfect in selecting raw materials and unique in compatibility of medicines, aims at pathogeny of nephritis such as spleen-kidney-yang deficiency, urination disorder, and retention of damp-heat in the interior, has effects on clearing heat and promoting diuresis, detoxifying and treating stranguria, inducing diuresis to alleviate edema, tonifying kidney and nourishing blood. The kidney essence pill is prepared through reasonable combination of raw materials. Clinical verification shows that the kidney essence pill has good absorption effect, obvious curative effect, no toxic and side effects, and no clinical adverse reaction, meets clinical requirements, is an ideal pill for curing kidney.

The purpose of the present invention is to provide a medicinal agent which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and/or urination disorders. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders containing the extract as an active ingredient. The medicinal agent of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders.

The invention relates to a preparation method of doxazosin mesylate controlled release tablets for treating urination disorder caused by prostatic hyperplasia, and belongs to the field of medicines. The invention provides a low-cost preparation method for doxazosin mesylate controlled release tablets.

[Problem] To provide a compound that has the effect of inhibiting PDE9 and is useful as an active ingredient in a therapeutic and/or prophylactic agent for urine collection disorders, urination disorders, diseases of the bladder and urinary system, and the like. [Solution] Investigating compounds that have the effect of inhibiting PDE9 and are useful as active ingredients in a therapeutic and/or prophylactic agent for urine collection disorders, urination disorders, diseases of the bladder and urinary system, and the like, the inventors of the present invention verified that an imidazoquinoxaline compound or a triazolo-quinoxaline compound has the effect of inhibiting PDE9, thereby completing the present invention. This imidazoquinoxaline compound or triazolo-quinoxaline compound has the effect of inhibiting PDE9 and can be used a therapeutic and/or prophylactic agent for urine collection disorders, urination disorders, diseases of the bladder and urinary system, and the like.

The present invention discloses one kind of medicine composition prepared with ginseng or American ginseng, ginkgo and other isogenous medicine and food botanic materials and through extraction in alcohol solution or water, concentration of the extract, drying and other steps. The medicine composition can eliminate BPH caused urinary dysfunction, and has no toxicity and less side effects. It may be used in preparing medicine and health food for eliminating BPH caused urinary dysfunction.

To provide a therapeutic agent for diseases associated with Nav 1.7, specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, urination disorders and multiple sclerosis. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, each of R1a,R1b, R1c and R1d represents a hydrogen atom, a halogen atom, a cyano group, a C1-4 alkyl group, a C1-4 alkoxy group or the like, provided that at least one of the R1a, R1b, R1c and R1d moieties represents a C6-10 aryl group, a C6-10 aryloxy group or the like; each of R2 and R3 represents a hydrogen atom, a C1-6 alkyl group, a C3-10 cycloalkyl group or the like; R4 represents a hydrogen atom, a C1-6 alkyl group, a C3-7 cycloalkyl group or the like; m represents 1, 2 or 3; L represents a CR7R8 group; and each of R7 and R8 represents a hydrogen atom, a hydroxyl group, a C1-4 alkyl group, a C1-4 alkoxy group or the like.)

The present invention relates to an agent for preventing and/or treating diabetic neuropathy comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and/or treating diabetic neuropathy, and particularly useful for providing an agent for preventing and/or treating diabetic motor neuropathy (such as muscle weakness disorder (such as muscle weakness disorder with inability to walk independently)), diabetic sensory neuropathy (such as paresthesia (such as vibration perception abnormality), allodynia, hypoesthesia (such as numbness of extremities or cold sensation), or pain), or diabetic autonomic neuropathy (such as stool abnormality (such as constipation or diarrhea), urination disorder, impotence, orthostatic hypotension, sudomotor dysfunction, abnormal heart rate variability, or delayed gastric emptying). Further, the invention is particularly useful for providing an agent for improving pathophysiology of diabetic neuropathy.

The invention relates to a tamsulosin hydrochloride sustained-release pellet. The tamsulosin hydrochloride sustained-release pellet comprises a medicine-containing pellet body and a coating layer, wherein the coating layer wraps the medicine-containing pellet body, the medicine-containing pellet body comprises tamsulosin hydrochloride, a blank pellet core, a filling agent, a lubricating agent and an adhering agent, and the coating layer comprises Eudragit NE30D and talcum powder. A preparation method comprises the following steps: 1, preparing materials; 2, mixing; 3, preparing the adhering agent; 4, pelleting; 5 preparing a coating agent; 6, coating; 7, filling; and 8, packaging by aluminum-plastic for obtaining a finished product. The tamsulosin hydrochloride sustained-release pellet is suitable for the symptoms such as urination disorder caused by benign prostatic hyperplasia, and is good in drug release stability, small in irritation to the gastrointestinal tract, good in bioavailability, convenient to package, transport and store, and suitable for industrial production. The tamsulosin hydrochloride sustained-release pellet is good in absorption after oral medication, and although the tamsulosin hydrochloride sustained-release pellet can be taken on an empty stomach or after the meal, food can increase the total absorptive amount of the tamsulosin hydrochloride sustained-release pellet.

The invention provides a compound preparation, which is applied to prevention and/or treatment of female perimenopausal urogenital syndrome and comprises the following main components: epidermal growth factors, sea buckthorn seed oil and glycerol. The invention further provides novel application of the compound preparation, namely application of the compound preparation in prevention and/or treatment of the female perimenopausal urogenital syndrome and application of the compound preparation in products of the female perimenopausal urogenital syndrome. Application in preventing and/or treating female vaginal atrophy, maintaining the state of sexual organs and in products thereof; the invention also relates to an application in prevention and/or treatment of urination disorders such as abnormal urination function, frequent urination, urgent urination and increased nocturnal urination in the perimenopausal period of women and an application in products thereof, and an application in improvement of sex hormone level in the perimenopausal period of women, regulation and recovery of disordered menstrual cycle of women and an application in products thereof. The application provides a basis for preventing and treating the perimenopausal urogenital syndrome by directly utilizing the compound preparation.

To provide a compound useful as an MC4 receptor agonist. The present inventors have made studies on MC4 receptor agonists. As a result, it is confirmed that a piperazine derivative has an MC4 receptoragonist activity, which leads to the accomplishment of the present invention. The piperazine derivative according to the present invention has an MC4 receptor agonist activity, and therefore can be used as a prophylactic or therapeutic agent for disturbance of urination in bladder and urinary tract diseases, particularly underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-sphincter dyssynergia and prostatic hyperplasia.

The invention relates to a noninvasive bladder pressure measuring device and a measuring method thereof. The measuring method comprises the following steps of: (1) connecting the measuring device, and inserting and fixing a pressure sensor probe into a water injection soft valve of a urethral catheter; (2) correcting the pressure value in a water bag to be 0 as a measurement initial pressure value; (3) acquiring the pressure in the bladder in real time, and calculating and predicting urination time in real time through a prediction model; and (4) outputting the predicted urination time, giving an alarm sound or outputting a pressure curve. The invention provides a bladder pressure monitoring device capable of noninvasively predicting the time of catheterization in real time and judging a urination disorder type, and a measuring method of the bladder pressure monitoring device. The bladder pressure monitoring device comprises a bladder pressure visualization system which continuously displays the bladder pressure and displays a time-pressure value in a curve form; and a built-in regression prediction model is used for calculating relative time when safe pressure is achieved, and a timely early warning is given to guide a patient or a caregiver thereof to open the urinary catheter in time, so that urine backflow is avoided.

The invention belongs to refractory surgical diseases of traditional Chinese medicine and provides a traditional Chinese medicine compounded oral preparation for treating chronic non-bacterial prostatitis and a preparation process therefor. The traditional Chinese medicine compounded oral preparation comprises the following raw materials in parts by weight: 15-50 parts of rhizoma smilacis glabrae,10-30 parts of lonicera japonica, 10-30 parts of rhizoma dioscoreae hypoglaueae, 10-30 parts of herba lysimachiae, 10-30 parts of herba verbenae, 10-30 parts of giant knotweeds, 10-30 parts of cowherb seeds and 5-20 parts of spina gleditsiae. The traditional Chinese medicine compounded oral preparation not only can be used for improving clinical symptoms such as pain discomfort and urination disorder, but also has a remarkable treatment effect in the aspects of improving quality of life and reducing a WBC count in EPS. Discovered through clinical researches, the traditional Chinese medicine compounded oral preparation provided by the invention has a good healing effect on the chronic non-bacterial prostatitis, the effective rate can reach up to 91.4% after 1 month of use, and the recurrence rate is low; and the oral administration is simple, and the traditional Chinese medicine compounded oral preparation is directly taken with warm water, reaches a focus, and is easily taken by a sufferer.

The invention relates to an electrical and magnetic stimulator for improving urinary retention. The stimulator comprises a main control module, an interaction module, an electrical stimulation circuit, a magnetic stimulation circuit, electrode slices and magnetic pole pieces, wherein the output end of the main control module is connected with the input ends of the electrical stimulation circuit and the magnetic stimulation circuit; the output end of the electrical stimulation circuit is connected with the plurality of electrode slices through wires; the output end of the magnetic stimulation circuit is connected with the plurality of magnetic pole pieces; the main control module is also connected with the interaction module; and an overcurrent protection circuit is connected in parallel between a main control chip and a power amplifier. The advantages of electrical stimulation and magnetic stimulation are combined; a therapeutic apparatus combining electrical stimulation and magnetic stimulation is provided; the electrical stimulation acts on the muscle functions of the bladder and the pelvic floor muscles; and the spinal cord function is regulated and controlled through the magnetic stimulation, so that the spinal cord, the bladder and the pelvic floor muscles are coordinated with one another to jointly complete the urination function, the adjustment is the same as the adjustment of urination of the normal human body, the urination disorder is improved, the bladder function is gradually improved, and the urinary retention and urinary incontinence are treated.

Disclosed are compounds which have PDE9 inhibitory activity and are useful as the active ingredient of therapeutics and/or preventives for urine collection disorder, urination disorder, bladder/urinary tract diseases and so on. As the results of studies on compounds having PDE9 inhibitory activity and being useful as the active ingredient of therapeutics and/or preventives for urine collection disorder, urination disorder, bladder/urinary tract diseases and so on, it is confirmed that an imidazoquinoxaline compound or a triazoloquinoxaline compound has PDE9 inhibitory activity. The aforesaid imidazoquinoxaline compound or triazoloquinoxaline compound has PDE9 inhibitory activity and is usable as preventives and/or therapeutics for urine collection disorder, urination disorder, bladder/urinary tract diseases and so on.

Disclosed is an EP1 antagonist, particularly a compound represented by the formula (I):

a salt thereof, a solvate thereof or a prodrug thereof. The compound, a salt thereof, a solvate thereof or a prodrug thereof is effective for prevention, treatment and/or symptom improvement of a dysuria (e.g., slow stream, splitting or spraying of the urine stream, intermittent stream, hesitancy, straining to void or terminal dribble).